Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$90.77

-2.32 (-2.49%)

, NVS

Novartis

$82.21

-2.18 (-2.58%)

16:34
10/11/18
10/11
16:34
10/11/18
16:34

AbbVie announces Humira patent dispute resolution, terms not stated

AbbVie (ABBV) announced a global resolution of all intellectual property-related litigation with Novartis (NVS) unit Sandoz over its proposed biosimilar adalimumab product. Under the terms of the settlement agreements, AbbVie will grant to Sandoz a non-exclusive license to AbbVie's intellectual property relating to HUMIRA beginning on certain dates in certain countries in which AbbVie has intellectual property. The license period will begin on September 30, 2023 in the U.S., and will not be accelerated by the entry of companies who have already taken a license. The license will begin on October 16, 2018 in most countries in the European Union, and on other dates in various countries in which AbbVie has intellectual property. Sandoz will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity of the licensed patents. AbbVie will make no payments to Sandoz. The precise terms are confidential between the parties. All litigation pending between the parties will be dismissed.

ABBV

AbbVie

$90.77

-2.32 (-2.49%)

NVS

Novartis

$82.21

-2.18 (-2.58%)

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

ABBV AbbVie
$90.77

-2.32 (-2.49%)

09/19/18
PIPR
09/19/18
NO CHANGE
Target $100
PIPR
Neutral
Piper more worried about AbbVie co-pay accumulator risk than California suit
While shares of AbbVie may move lower today on news of California's insurance regulator suing the company over promotion of Humira, a more fundamental potential drag on Humira remains the advent of co-pay accumulators, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst sees the California lawsuit as more headline risk than anything but thinks "it may nevertheless serve as a minor overhang on shares." He points out that new research this week by Drug Channels suggests that more than one-third of commercial lives are enrolled in plans that have implemented copay accumulators for 2018, higher than his prior best estimate of 17%. Raymond keeps a Neutral rating on AbbVie with a $100 price target.
09/19/18
FBCO
09/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's California lawsuit may have broader implications, says Credit Suisse
After the State of California has filed a lawsuit against AbbVie, accusing the company of paying kickbacks to doctors and using a network of nurses to illegally boost Humira prescriptions, Credit Suisse analyst Vamil Divan said he is "not surprised" by the stock's weakness given how leveraged it is to Humira sales and profit, and think there could be additional weakness as the story develops, especially if other states file similar lawsuits against the company. Additionally, he wonders how lawsuits like this may impact marketing practices across the industry. Divan maintains a cautious view on the stock with an Underperform rating and $85 price target, and says he continues to have concerns about the sustainability of Humira given the expected entry of multiple biosimilars in the EU next month expected biosimilar pressure in the U.S. starting in 2023.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
NVS Novartis
$82.21

-2.18 (-2.58%)

09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Novartis initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Novartis with a Neutral rating and CHF 94 price target, stating that its Alcon spin likely will generate value, but he believes additional pipeline catalysts are needed to drive operating leverage.

TODAY'S FREE FLY STORIES

02:35
10/19/18
10/19
02:35
10/19/18
02:35
General news
FX Update: The Dollar has held firm against most currencies »

FX Update: The Dollar…

01:40
10/19/18
10/19
01:40
10/19/18
01:40
General news
Asian Market Wrap: »

Asian Market Wrap:…

22:20
10/18/18
10/18
22:20
10/18/18
22:20
General news
China's GDP slowed to a 6.5% y/y growth pace in Q3 »

China's GDP slowed…

NI

NiSource

$25.25

0.22 (0.88%)

21:12
10/18/18
10/18
21:12
10/18/18
21:12
Downgrade
NiSource rating change at Goldman Sachs »

NiSource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PNW

Pinnacle West

$83.48

-0.235 (-0.28%)

21:04
10/18/18
10/18
21:04
10/18/18
21:04
Upgrade
Pinnacle West rating change at Goldman Sachs »

Pinnacle West upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

NVS

Novartis

$86.24

0.9 (1.05%)

20:26
10/18/18
10/18
20:26
10/18/18
20:26
Hot Stocks
Novartis granted orphan status for melanoma treatment »

The FDA granted Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

, HON

Honeywell

$155.22

-2.73 (-1.73%)

20:25
10/18/18
10/18
20:25
10/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

HON

Honeywell

$155.22

-2.73 (-1.73%)

SLB

Schlumberger

$58.43

-0.81 (-1.37%)

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

STT

State Street

$79.62

-2.5 (-3.04%)

STI

SunTrust

$61.46

-0.94 (-1.51%)

SYF

Synchrony

$29.63

-0.45 (-1.50%)

CFG

Citizens Financial

$34.92

-0.96 (-2.68%)

KSU

Kansas City Southern

$102.68

-1.31 (-1.26%)

IPG

Interpublic Group

$22.48

0.28 (1.26%)

EEFT

Euronet

$112.64

-2.96 (-2.56%)

MAN

Manpower

$78.38

-1.09 (-1.37%)

GNTX

Gentex

$18.62

-0.32 (-1.69%)

CLF

Cleveland-Cliffs

$11.47

-0.37 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 26

    Nov

  • 26

    Nov

  • 06

    Dec

  • 03

    Mar

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

20:24
10/18/18
10/18
20:24
10/18/18
20:24
Upgrade
Canadian Pacific rating change at National Bank »

Canadian Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

19:57
10/18/18
10/18
19:57
10/18/18
19:57
Hot Stocks
DowDuPont clarifies the charge is the result of previously reported conditions »

In response to market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

19:35
10/18/18
10/18
19:35
10/18/18
19:35
Downgrade
Valero Energy Partners rating change at RBC Capital »

Valero Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

IVZ

Invesco

$21.26

0.32 (1.53%)

19:33
10/18/18
10/18
19:33
10/18/18
19:33
Downgrade
Invesco rating change at Credit Suisse »

Invesco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

LOGC

LogicBio Therapeutics

$0.00

(0.00%)

19:31
10/18/18
10/18
19:31
10/18/18
19:31
Syndicate
LogicBio Therapeutics 7M share IPO priced at $10.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MDSO

Medidata

$70.91

1.54 (2.22%)

19:07
10/18/18
10/18
19:07
10/18/18
19:07
Recommendations
Medidata analyst commentary at JPMorgan »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$263.85

-8.09 (-2.97%)

18:58
10/18/18
10/18
18:58
10/18/18
18:58
Periodicals
Tesla rolls out new Model 3 with 'mid-range' battery pack, Electrek reports »

Tesla today is rolling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Dec

SKX

Skechers

$26.05

-0.64 (-2.40%)

, PYPL

PayPal

$77.50

-2.61 (-3.26%)

18:51
10/18/18
10/18
18:51
10/18/18
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$26.05

-0.64 (-2.40%)

PYPL

PayPal

$77.50

-2.61 (-3.26%)

CE

Celanese

$97.01

-2.76 (-2.77%)

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

ISRG

Intuitive Surgical

$522.41

-20.44 (-3.77%)

AXP

American Express

$102.86

-1.53 (-1.47%)

ETFC

E-Trade

$48.89

-1.68 (-3.32%)

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

VLO

Valero

$103.31

-0.36 (-0.35%)

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

OZK

Bank OZK

$34.85

-1.57 (-4.31%)

LLNW

Limelight Networks

$5.07

0.12 (2.42%)

TEAM

Atlassian

$81.96

-1.67 (-2.00%)

AIG

AIG

$48.62

-0.99 (-2.00%)

SREV

ServiceSource

$2.60

-0.08 (-2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 29

    Oct

  • 05

    Nov

  • 07

    Nov

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 05

    Dec

  • 06

    Dec

X

U.S. Steel

$27.91

-0.27 (-0.96%)

, AKS

AK Steel

$4.69

-0.115 (-2.39%)

18:47
10/18/18
10/18
18:47
10/18/18
18:47
Periodicals
U.S. requests WTO panel to examine metals tariffs retaliation, Reuters says »

The U.S. has asked the…

X

U.S. Steel

$27.91

-0.27 (-0.96%)

AKS

AK Steel

$4.69

-0.115 (-2.39%)

NUE

Nucor

$58.26

-0.85 (-1.44%)

STLD

Steel Dynamics

$41.32

0.77 (1.90%)

AA

Alcoa

$38.85

2.14 (5.83%)

CENX

Century Aluminum

$9.91

-0.23 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 25

    Oct

  • 26

    Oct

  • 02

    Nov

RLH

Red Lion Hotels

$12.62

-0.42 (-3.22%)

18:43
10/18/18
10/18
18:43
10/18/18
18:43
Hot Stocks
Red Lion Hotels CFO Douglas Ludwig resigns due to personal health reasons »

RLH Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

IDA

IDACORP

$96.78

0.035 (0.04%)

18:30
10/18/18
10/18
18:30
10/18/18
18:30
Hot Stocks
IDACORP declares quarterly dividend of 63c per share »

Director of IDACORP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$20.70

-0.59 (-2.77%)

18:08
10/18/18
10/18
18:08
10/18/18
18:08
Syndicate
Krystal Biotech 3M share Secondary priced at $20.00 per share »

Cowen, William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

, SVU

Supervalu

$32.49

0.02 (0.06%)

18:05
10/18/18
10/18
18:05
10/18/18
18:05
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

SVU

Supervalu

$32.49

0.02 (0.06%)

UNFI

United Natural Foods

$26.94

0.2 (0.75%)

TTGT

TechTarget

$19.53

-0.35 (-1.76%)

PERY

Perry Ellis

$27.48

0.02 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 28

    Oct

  • 07

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

SXT

Sensient

$76.67

-1.15 (-1.48%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
Sensient raises quarterly dividend to 36c from 33c per share »

The cash dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
DowDuPont says Sept. quarter results won't be impacted by $4.5B goodwill charge »

On October 18, 2018, E.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$3.54

-0.13 (-3.54%)

17:55
10/18/18
10/18
17:55
10/18/18
17:55
Hot Stocks
Northern Oil and Gas sees Q4 production 58% greater than Q2 »

Liquidity has increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SHPG

Shire

$176.90

-0.4 (-0.23%)

17:47
10/18/18
10/18
17:47
10/18/18
17:47
Hot Stocks
FDA advisory committee recommends Shire's Prucalopride for CIC »

Shire announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 21

    Dec

ACN

Accenture

$156.20

-2.76 (-1.74%)

, T

AT&T

$32.50

-0.06 (-0.18%)

17:37
10/18/18
10/18
17:37
10/18/18
17:37
Hot Stocks
CACI, IBM, Northrop Grumman and more compete for orders on $37.4B Army contract »

Accenture Federal…

ACN

Accenture

$156.20

-2.76 (-1.74%)

T

AT&T

$32.50

-0.06 (-0.18%)

CACI

CACI

$181.34

-2.07 (-1.13%)

HII

Huntington Ingalls

$233.27

0.15 (0.06%)

CMTL

Comtech

$32.05

-0.95 (-2.88%)

IBM

IBM

$130.52

-3.53 (-2.63%)

JEC

Jacobs Engineering

$73.01

-0.89 (-1.20%)

KFRC

Kforce

$35.15

-0.49 (-1.37%)

LLL

L3 Technologies

$218.17

-1.965 (-0.89%)

LDOS

Leidos

$66.72

-0.97 (-1.43%)

NOC

Northrop Grumman

$308.21

-1.04 (-0.34%)

RTN

Raytheon

$191.62

-1.48 (-0.77%)

KEYW

KEYW

$8.31

-0.27 (-3.15%)

VSEC

VSE Corp.

$30.75

-1.13 (-3.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.